Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2007-02-13
2007-02-13
Richter, Johann (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S566000
Reexamination Certificate
active
10617943
ABSTRACT:
This invention relates to the methods and pharmaceutical compositions for treating diseases or disorders associated with oxidative stress and/or genomic instability. In particular, the invention relates to methods for treating ataxia-telangeictasia (AT) and such disease states by administering a therapeutically effective amount of a chelating agent to increase genomic stability and/or decrease oxidative stress.
REFERENCES:
Shackelford et al. Desferrioxamine treatment increases the genomic stability ofAtaxia-telangiectasiacells, DNA Repair, Sep. 18, 2003, vol. 2, pp. 971-981.
Weil et al., Radiation Induces Genomic Instability and Mammary Ductal Dysplasia in ATM Heterozgous Mice, 2001, Oncogene, vol. 20, 4409-4411.
Shackelford, Rodney et al. “Desferrioxamine treatment increases the genomic stability ofAtaxia-telangiectasiacells” ScienceDirect, DNA Repair, vol. 2, Issu 9, Sep. 2003, pp. 971-981.
Simpson, Marty “Buck Researcher Links Iron to Parkinson's Disease” Buck Institute, Neuron Mar. 26, 2003.
Polla, Ada S., et al. “Iron as the malignant spirit in successful ageing” Ageing Research Reviews 2(2003) 25-37.
Young, Ian.S., et al. “The effects of desferrioxamine and ascorbate on oxidative stress in the streptozotocin diabetic rat” ScienceDirect, Free Radical Biology and Medicine, vol. 18, Issue 5, May 1995, pp. 833-840.
Kaur, Deepinder et al. “Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo” Science Direct, Neuron, vol. 37, Issue 6, Mar. 27, 2003, pp. 899-909.
Wong, Alice PhD, et al. “Oxidative Stress in Friedreich'sAtaxia: Mechanisms and Potential Therapy” Friedreich'sAtaxia(FRDA) NAF 1999.
Naughton, D.P., “Iron(III)-mediated intra-articular crystal deposition in arthritis: a therapeutic role for iron chelators” ScienceDirect, Medical Hypotheses, vol. 57, Issue 1, Jul. 2001, pp. 120-122.
Duffy, SJ, et al. “Iron chelation improves endothelial function in patients with coronary artery disease.” Entrez-Pub-Med, Abstract Jun. 12, 2001.
Kuperstein, Faina et al., “Pro-apoptotic signaling in neuronal cells following iron and amyloid beta peptide neurotoxicity” Journal of Neurochemistry, vol. 86, No. 1, 2003 114-125.
Cameron, NE., et al. “Neurovascular dysfunction in diabetic rates. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents.” ABSTRACT Entrez-PubMed, J. Clin. Invest. Aug. 1995;96(2); 1159-63.
Buss, Joan L., et al. “The Role of Iron Chelation in Cancer Therapy” Abstract—Currently Medicinal Chemistry, vol. 10, No. 12, 2003.
Shackelford Rodney E.
Wang Suming
Handy Nikki
McKee Voorhees & Sease, P.L.C.
Richter Johann
Wang Suming
LandOfFree
Methods and compositions for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3831251